文献速递前列腺癌

低体积转移性激素敏感性前列腺癌的前列腺放疗:一项网络Meta分析

Prostate Radiotherapy in Low-volume Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis.
PubMed 文献 · Eur Urol · 2024-04-03

该系统评价与网络Meta分析纳入10项随机对照试验共4423例低体积转移性激素敏感性前列腺癌患者,比较标准治疗(ADT或ADT联合多西他赛)基础上加用雄激素受体通路抑制剂(ARPI)和/或前列腺放疗的总生存。在未使用多西他赛的新发转移人群中,标准治疗联合ARPI联合放疗对比标准治疗联合ARPI的风险比为0.76(95%可信区间0.51-1.16),证据尚不充分;需个体患者数据Meta分析或随机对照试验确认。

要点

  • 在低体积新发转移性激素敏感性前列腺癌且未用多西他赛人群中,标准治疗联合ARPI联合放疗对比标准治疗联合ARPI的风险比为0.76(95%可信区间0.51-1.16)。
  • 同一人群中,标准治疗联合放疗对比标准治疗联合ARPI的风险比为1.10(95%可信区间0.92-1.42),未发现足够证据支持差异。
  • 四种策略的累积排名曲线下面积分别为标准治疗0.0006、标准治疗联合放疗0.45、标准治疗联合ARPI0.62、标准治疗联合ARPI联合放疗0.94。

核心结论

  • 在低体积新发转移性激素敏感性前列腺癌患者中,有一些证据表明标准治疗联合ARPI联合放疗对比次优策略标准治疗联合ARPI可降低死亡风险。
  • 需要个体患者数据Meta分析或随机对照试验来确认这些发现。

研究设计与样本

  • 该系统评价与网络Meta分析检索了截至2023年7月的文献数据库和会议论文集,纳入评估在标准治疗(定义为ADT或ADT联合多西他赛)基础上加用ARPI或前列腺放疗用于转移性激素敏感性前列腺癌初始治疗的随机对照试验。
  • 分析仅聚焦于这些试验中低体积转移性激素敏感性前列腺癌亚组的汇总数据,将治疗臂合并为四组:标准治疗、标准治疗联合ARPI、标准治疗联合放疗、标准治疗联合ARPI联合放疗。
  • 共纳入10项随机对照试验,包含4423例患者;主要结局为总生存,采用固定效应贝叶斯网络Meta分析进行比较,并采用贝叶斯网络Meta回归校正试验间标准治疗中多西他赛使用比例和新发转移患者比例的差异。

主要发现

  • 四种策略的累积排名曲线下面积分别为标准治疗0.0006、标准治疗联合放疗0.45、标准治疗联合ARPI0.62、标准治疗联合ARPI联合放疗0.94。
  • 在Meta回归中,对于新发转移性激素敏感性前列腺癌且未使用多西他赛的人群,未发现足够证据表明标准治疗联合ARPI联合放疗对比标准治疗联合ARPI在总生存上有差异(风险比0.76;95%可信区间0.51-1.16)。
  • 同一人群中,未发现足够证据表明标准治疗联合放疗对比标准治疗联合ARPI在总生存上有差异(风险比1.10;95%可信区间0.92-1.42)。

临床怎么用

  • 作者认为,在低体积新发转移性激素敏感性前列腺癌患者中,有一些证据表明标准治疗联合ARPI联合放疗对比标准治疗联合ARPI可降低死亡风险,但需个体患者数据Meta分析或随机对照试验确认。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: The utility of prostate radiotherapy (RT) is unclear in men with metastatic hormone-sensitive prostate cancer (mHSPC) receiving intensified systemic therapy with androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPIs). We performed a network meta-analysis of randomized controlled trials (RCTs) to investigate the role of prostate RT in low-volume mHSPC. METHODS: Bibliographic databases and conference proceedings were searched through July 2023 for RCTs evaluating the addition of ARPIs or prostate RT to standard of care (SOC) systemic therapy, defined as ADT or ADT plus docetaxel, for the initial treatment of mHSPC. We focused exclusively on aggregate data from the low-volume mHSPC subpopulation in these trials. We pooled the treatment arms into four groups: SOC, SOC plus ARPI, SOC plus RT, and SOC plus ARPI plus RT. The primary outcome was overall survival (OS). To compare treatment strategies, a fixed-effects Bayesian network meta-analysis was undertaken, while a Bayesian network meta-regression was performed to account for across-trial differences in docetaxel use as part of SOC and in proportions of patients with de novo presentation. KEY FINDINGS AND LIMITATIONS: Ten RCTs comprising 4423 patients were eligible. The Surface Under the Cumulative Ranking Curve scores were 0.0006, 0.45, 0.62, and 0.94 for SOC, SOC plus RT, SOC plus ARPI, and SOC plus ARPI plus RT, respectively. On a meta-regression, in a population with de novo mHSPC and no docetaxel use, we did not find sufficient evidence of a difference in OS between SOC plus ARPI plus RT versus SOC plus ARPI (hazard ratio [HR]: 0.76; 95% credible interval: 0.51-1.16) and SOC plus RT versus SOC plus ARPI (HR: 1.10; 95% credible interval: 0.92-1.42). CONCLUSIONS AND CLINICAL IMPLICATIONS: There was some evidence that SOC plus ARPI plus RT reduced mortality compared with the next best strategy of SOC plus ARPI in patients with low-volume de novo mHSPC. A meta-analysis with individual patient data or an RCT is needed to confirm these findings.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Roy S, Fervaha G, Spratt DE, et al. Prostate Radiotherapy in Low-volume Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis. Eur Urol. 2024. PMID: 38570246. doi:10.1016/j.eururo.2024.03.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。